GLUE Monte Rosa Therapeutics, Inc.
$10.66▲ +1.72%
Healthcare
Other
After hours
$10.66▲ +0.00%
Oct 27, 4:42 PM ET
Volume 1.46M
Avg Volume (10D) 1.44M
Key Metrics & Fundamentals
Market Cap
$909.44M
P/E Ratio
–
Div Yield
0.00%
52W Range
9.68 - 25.77
% vs 50 MA
-13.60%
% vs 200 MA
-39.35%
RSI-14
43.3
MACD Histogram
+0.2100
Beta (1Y vs SPY)
0.94
Free Cash Flow
-$48.84M
Gross Rev
$8.97M
Gross Profit
$8.97M
EBITDA
-$47.24M
COGS
–
Operating Exp
$58.10M
Operating Income
-$49.13M
EBIT
-$49.13M
Pretax Income
-$43.19M
Net Income
-$43.40M
EPS (Diluted)
-0.51
Price & Volume History
Loading chart…
Recent News
Could You Have Seen The Run In Kymera Stock Coming?
Trefis · Oct 26, 2026 5:34 PM ET
Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
Zacks · Oct 23, 2026 6:51 AM ET
UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating
MT Newswires · Oct 12, 2026 10:02 AM ET
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
MarketBeat · Oct 6, 2026 3:02 AM ET
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:01 PM ET
Sector Update: Healthcare Stocks Decline Premarket Thursday
MT Newswires · Oct 1, 2026 9:17 AM ET
Sector Update: Healthcare
MT Newswires · Oct 1, 2026 8:59 AM ET
Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study
MT Newswires · Oct 1, 2026 8:18 AM ET
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
GlobeNewswire · Oct 1, 2026 7:00 AM ET
HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target
MT Newswires · Oct 1, 2026 6:31 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See GLUE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.